中  文
Stock Short Name:Hybio Pharmaceutical | Stock Exchange Code:300199
OA系统

Development History

2003

Hybio passed the examination successfully and obtained the Drug Manufacturing Certificate and the Drug GMP Certificate; Hybio undertook the Guangdong Major Breakthrough Project in Key Areas.

2004

Two projects, which were respectively about the large-scale preparation technology of polypeptides and the high-tech industrialization of novel polypeptide drugs, were approved as “National Demonstration Project of High-Tech Industrialization; Some projects entered the large-scale production process and the related polypeptide drugs started to be sold.

2005

The National High-Tech Research and Development Project (863) and the National “Tenth five” Municipal Science and Technology Project undertaken by Hybio successfully passed the acceptance of the Ministry of Science and Technology; The peptide R&D center was approved as Guangdong R&D Center of Engineering Technology.

2006

The National High-Tech Industrialization Project undertaken by Hybio passed the acceptance of National Development and Reform Commission.

2007

The large-scale manufacturing base of polypeptide drugs was approved as the National Demonstration Project of High-Tech Industrialization;Hybio successfully passed the inspection of the third on-site meeting for National Specific Rectification of Product Quality and Food Safety; Hybio undertook the National “Eleventh five” Municipal Science and Technology Project.

2008

Hybio cooperated with SAIF Partners and Shenzhen Capital Group for strategic financing, and raised 15 million USD from venture capital funds in the series A financing; Guangdong Engineering Technology R&D Center of Polypeptide Drugs successfully passed the acceptance; Hybio was awarded the title of “Leading Enterprise of the Independent Innovative Industry in Shenzhen” by Shenzhen Municipal Government

2009

Hybio was identified as “National High-Tech Enterprise”; Hybio Undertook or participated in three major scientific and technological projects of National Major Project for New Drug Innovation and Development, and two national high-tech industrialization projects; Hybio won “Guangdong Provincial Science and Technology Award Second Prize”; The stock share reconstruction was completed.

2010

Hybio was awarded the title of “National Demonstration Project of High-Tech Industrialization” by National Development and Reform CommissionHybio was one of the“Deloitte Top 500 High-growth Enterprises in Asia-Pacific Region”; Hybio was elected as one of “The Chinese Top 200 Potential Enterprises in 2010”by Forbes.

2011

Hybio launched its IPO and began to be listed on GEM with the approval of China Securities Regulatory Commission, and became the first listed enterprise of manufacturing polypeptide drugs in China; Hybio was elected as one of the “Guangdong Top 500 Enterprises”; The R&D Center was identified as National and Local Joint Engineering Laboratory by National Development and Reform Commission.

2012

Hybio was on the “Forbes List of Chinese Most Potential Enterprises in 2012”; The manufacturing base of polypeptide drugs was listed as the project in “National Key Industry Revitalization Plan”; The construction of large-scale comprehensive pharmaceutical compound library was listed as “National Special Project to Develop the Generic Drugs; Hybio also won “Shenzhen Science and Technology Progress Award” and “Shenzhen Patent Award of Science and Technology”; Hybio Pharmaceutical (HK) Limited was registered.

2013

The manufacturing base of polypeptide drugs successfully passed the certification of new GMP as well as obtained the Drug Manufacturing Certificate and the GMP Certificate; Pingshan Branch of Hybio Pharmaceutical (Shenzhen) Co., LTD was foundedHybio won the award of “Top 100 of Taxpayers of Nanshan District in 2012”; Hybio won the “Gold Shield-Investor Relation Award of Chinese Listed Companies in 2013”.

2014

Hybio won the“Forbes Award of Chinese Most Potential Enterprise”; Hybio Pharmaceutical (Wuhan) Co., LTD was registered.